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ABSTRACT 
Objective: The solubility of a drug in water plays an important role in the absorption of the drug after oral administration. Cocrystal is one method 
that improves the solubility of the active pharmaceutical ingredient (API). The aim of this study was to investigate the formation of a glibenclamide 
(GCM)-aspartame (APM) cocrystal using the solvent evaporation method and to evaluate its solubility and dissolution rate.  
Methods: Molecular docking of the GCM-APM cocrystal was observed using an in silico method. The GCM-APM cocrystal (1:2) was prepared by 
using the solvent evaporation method. The cocrystal of GCM-APM was evaluated by the saturated solubility test and the dissolution rate test (USP 
type 2 apparatus). The solvent evaporation product of GCM-APM was characterized by Fourier transform infrared spectroscopy (FT-IR), differential 
scanning calorimetry (DSC), and powder X-ray diffraction (PXRD).  
Results: In silico study showed that the interaction of GCM-APM has hydrogen bonding and the potential to improve the solubility of GCM. 
Evaluation of the cocrystal of GCM-APM showed that the solubility and dissolution rate of the cocrystal are significantly increased. Characterization 
of FT-IR showed that no chemical reaction occurred in the GCM-APM cocrystal. The DSC analysis showed the changes in the melting point of GCM. 
Measurement of PXRD showed the formation of a new solid crystal phase that is different from GCM and APM.  
Conclusion: GCM-APM has hydrogen bonding can improve the solubility and dissolution rate of GCM.  
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Solubility is an important parameter of the absorption process of a 
drug in the gastrointestinal tract that affects the drug concentration 
that can reach the blood circulation. This is important because the 
effectiveness of a drug treatment depends on the level of drug in the 
blood. Drugs with poor solubility in water exhibit poor 
bioavailability and low dissolution rates in the drug absorption [1]. 
Almost 70% of new active pharmaceutical ingredients (API) show 
poor water solubility, which can cause poor dissolution in the GI 
fluids. Therefore, increasing the dissolution rate of poorly water-
soluble drugs is important in enhancing their bioavailability [2].  
Glibenclamide (GCM) (5-chloro-N-[2-[4-(cyclohexyl carbamoyl-
sulfamoyl) phenyl] ethyl]-2-methoxybenzamide) is a type 2 of 
antidiabetic drug used orally for controlling glycemia to treat non-
insulin dependent [3]. In the biopharmaceutical classification system 
(BCS), GCM is included in class II, which means it has a high 
permeability and a low solubility. The properties of GCM can 
produce poor dissolution rate and can result in low bioavailability. 
Several studies have been conducted to increase the solubility of 
GCM such as solid dispersion [4], surface solid dispersion, 
nanoparticles [5], and nanoemulsion [6]. However, none of these 
methods stably yield a solid preparation. 
One method that can increase the solubility of the API is cocrystal 
formation. Structurally, components of a cocrystal contain 
crystalline material present in a definite stoichiometric amount [7]. 
A cocrystal can improve solubility, dissolution rate, bioavailability, 
and stability because it has two or more neutral molecular 
constituents bonded together in the crystal lattice through hydrogen 
bonding [8]. Complex crystal formations were connected by a 
synthon that in pharmaceutical crystal engineering is called “a non-
covalent interaction involving hydrogen bonds, Van der Waals, and 
π-π electrons” [9]. For designing cocrystals, choosing a synthon in a 
cocrystal is important for the crystallization process. Using the in 
silico method for designing cocrystals can help predict the 
interaction of synthon between the API and the conformer [8].  
Improving bioavailability is desirable for an antidiabetic drug, especially 
GCM. Hence there is strong scientific and clinical need to prepare novel 
forms of GCM possessing modified solubility and dissolution rate, which 
can be formulated in tablet dossage form. Accordingly, the aim of the 
present study was to prepare a glibenclamide cocrystal by using the 
solvent evaporation method with aspartame as a coformer. Previous 
studies have proved that glibenclamide-oxalic acid cocrystals increase 
GCM solubility by up to sixfold [10]. In addition, the use of aspartame 
(APM) as a coformer was shown to increase atorvastatin solubility at the 
rate of 136.77% compared to atorvastatin [11].  
MATERIALS AND METHODS 
Material 
GCM was obtained from Indofarma (Indonesia) with a purity>99% 
and APM pro analysis was obtained from Merck (Germany). 
Methods 
In silico molecular docking 
Two-dimensional structures of GCM (Chem Spider ID: 54809) and 
coformers in. mol format were downloaded from www. chemspider. 
com. All. mol files of the molecules were converted into. pdb files by 
employing OpenBabelGUI 2.2.3. The files were then opened in 
AutoDock 4.2.3 and converted into. pdbq files by adding polar 
hydrogen and Kollman charges. The. pdbq files were converted into. 
pdbqt files by calculating their torsion angles, and were then ready 
to be used for docking. Docking was repeated five times for each 
coformer. Parameters observed were the type and energy (Ei) of 
interactions [11, 12] 
Preparation of cocrystal using solvent evaporation method  
GCM and APM were weighed in equimolar ratios of 1:1 and 1:2. Each 
compound was dissolved in methanol and mixed for a few minutes. 
An equimolar solution was evaporated using a water bath at 40 °C 
for 48 h. The obtained product was dried at room temperature 
overnight and further analyzed for its characterization [13].  
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Determination of solubility 
Cocrystal GCM equivalent to 50 mg was placed in an Erlenmeyer flask 
that contained water. Cocrystals were agitated in a mechanical shaker 
for 24 and 48 h at room temperature. The saturated solutions were 
filtered through a 0.45 μm membrane filter, and the amount of the drug 
dissolved was analyzed spectrophotometrically at 266 nm [1].  
Optimization of pH of GCM dissolution medium  
Phosphate buffer media was prepared at 900 ml with pH variations 
of 6.4, 7.6 and 8. The dissolution test was then performed on 
standard GCM using a dissolution tester type 2 (paddle) at 75 rpm 
for 60 min at 37±0.2 °C. At each time point (5, 10, 15, 30, 45 and 60 
min), samples of 5 ml were taken and then 5 ml of phosphate buffer 
media was re-added. The 5 ml samples taken were then measured 
by UV spectrophotometry (Analytical Jena, Germany) so that the 
amount of GCM concentration and the optimal pH of the medium 
could both be determined [14].  
Dissolution test 
Cocrystals of GCM were measured with a dissolution test (USP type 2 
apparatus). The sample of cocrystal was put into 900 ml of a buffered 
phosphate solution with a pH of 8 and stirred at 75 rpm. The dissolution 
samples were filtered through a syringe filter of 0.45 μm pore size and 
were measured periodically (at 0, 10, 15, 30, 45, and 60 min) and were 
analyzed spectrophotometrically at 266 nm [15].  
Characterization of cocrystal  
Fourier transform infrared spectroscopy (FT-IR) analysis  
Samples were mixed with potassium bromide crystal and crushed until 
homogeneous, and then compressed to a pressure of 20 psi. The infrared 
spectrum was obtained using an infrared spectrophotometer in a range 
of wavenumbers (400-4000 cm-1) using FT-IR [8, 9, 16] 
Powder X-ray diffraction (PXRD) analysis 
Powder X-ray diffraction (Phillips PW1835® diffractometer) 
analysis was performed at room temperature . The condition of 
measurement was set using Cu Ka radiation (l = 1.54 A)̊, a tube stage 
of 40 kV, and a tube current of 40 mA. Data were collected on the 
range of 2 theta of 5–40 ° at a scan rate of 1–2 °/min [8, 9, 17]. 
Differential scanning calorimetry (DSC) analysis  
Thermal analyses of cocrystal were performed on a DSC. A 
thermograph was recorded under a gas flow of 50 ml/min. Samples 
were analyzed from 30 to 200 °C with a heating rate of 10 °C/min 
[17, 18].  
Statistical analysis  
The data of the solubility test and dissolution rate test were 
presented as a mean of samples±standard deviation (SD) and were 
analyzed using the one-way analysis of variance (ANOVA) at the 
level of (P<0.05) to determine if the changes in the applied factors 
were statistically significant at the level of (p<0.05) and non-
significant at the level of (p>0.05)) [19].  
RESULTS  
Selection of coformers by an in silico method was used to predict the 
interaction between glibenclamide and a coformer molecularly. The 
results of an in silico method between GCM-APM and the prediction 




Fig. 1: In silico molecule modeling the simulation of GCM and APM 
 
 
Fig. 2: The interaction between GCM and APM 
 
The coformer used has no pharmacological activity and has an 
acceptor group and a hydrogen donor that is between GCM and 
coformer which allows the formation of a hydrogen bond [12].  
The interaction of hydrogen bonds formed between GCM and APM 
has an effect on the hydrophilicity of GCM [20]. The hydrogen atom 
in the secondary amine group of GCM functions as a hydrogen 
bonding donor, whereas the oxygen atoms in the APM hydroxyl 
group function as the hydrogen bond acceptor [10].  
The results of the solubility study of the GCM cocrystal can be seen 
in table 1. 
 
Table 1: The result of the solubility study of the GCM cocrystal (All the values were calculated as mean±standard deviation) (n=3) 
Sample Concentration (μg/ml) 
24 h 48 h 
Pure GCM 2.11+0.21 4.40+0.12 
Physical mixture of GCM-APM 13.51+0.76 18.72+0.54 
The Solvent evaporation Product of GCM-APM (1:1) 18.74+0.81 30.48+0.78 
The Solvent evaporation Product of GCM-APM (1:2) 31.71+1.15 60.63+1.21 
 
The result of the solubility test was analyzed statistically and 
showed that ρ value was less than 0,05; therefore, H0 was rejected 
and Ha
The formation of hydrogen bonds between GCM and APM causes 
increased solubility of GCM. The water-soluble aspartame properties 
also affect the increased solubility of GCM cocrystal in water [21]. 
Using a coformer will decrease the barrier on the crystal so that the 
dissolution process of GCM becomes easier. According to the 
previous study when the cocrystals are ionized, the pH changes 
because the ion of the cocrystal component changes the pH of the 
environment [22].   was accepted, which means that there were significant 
differences among each treatment (pure GCM versus cocrystal of 
GCM).  The dissolution test was performed on the cocrystal with the best 
equimolar ratio based on the solubility test, i.e., GCM-APM 1:2 
compared with pure GCM. Optimization of pH of dissolution medium 
was performed at pH 6.4, 7.6, and 8.0. In table 4, the concentration of 
standard GCM at 60 min was 9.91, 16.43, and 45.31 ppm for pH 6.4, 
7.6, and 8.0, respectively. Based on the results, 8.0 was the optimum 
pH for the dissolution test of GCM. 
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Fig. 3: Optimization of pH of dissolution medium (All the values were calculated as mean±standard deviation) (n=3), the results of the 
dissolution test for GCM can be seen in fig. 4 
 
 
Fig. 4: The results of the dissolution test for GCM cocrystal (All the values were calculated as a mean±standard deviation) (n=3) 
 
The result of the dissolution test was analyzed statistically and showed 
that the ρ value was less than 0.05; therefore, H0 was rejected and Ha
The increase of the dissolution rate of the glibenclamide-aspartame 
cocrystal is caused by the hydrogen bonding interaction in the co-
crystalline thus increasing the polarity of GCM In addition, the 
solubility of good APM in the water can affect the dissolution of GCM 
cocrystal [11]. Molecules in the physical mixture could become non-
random and organized, upon heating results in lowering of melting 
points. It indicated that the eutectic formation was accelerated by 
grinding. Increased surface contact between components after 
grinding induces a weaker eutectic interaction which requires lower 
activation energy to reach the melting point [23].  
 
was accepted, which means that there were significant differences 
among pure GCM compared to cocrystal of GCM and physical mixture. 
The results of the FTIR spectrum from GCM, APM and cocrystal of 
GCM-APM can be seen in fig. 5. 
  
 
Fig. 5: The results of the FTIR spectrum of GCM (blue), APM (red), GCM-APM cocrystal (black), analysis of functional groups from the FTIR 
results of the GCM cocrystal can be seen in table 2 
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Table 2: Analysis of functional groups from the FTIR results of the GCM cocrystal (n=3) 
No GCM APM GCM-APM cocrystal 
Peak (cm-1) Stretch  Peak (cm-1) Stretch  Peak (cm-1) Stretch 
1 3313.17  N-H Stretch 3275.13 N-H Stretch 3367.71 N-H Stretch 
2 3116.97 O-H Stretch 2931.8 C-H Stretch 3205.69 O-H Stretch 
3 2931.8 C-H Stretch 1696.35 C=O Stretch 2854.65 C-H Stretch 
4 1712,79  C=O Stretch   1593.20 C=O Stretch 
5 1612,49  C=C Stretch     1616.35 C=C Stretch 
 
When the formation of functional groups was compared between 
GCM-APM cocrystals, GCM, and APM, there was no new peak. This 
indicates that there is no new functional group and it can be 
predicted that no chemical reaction occurred in the GCM cocrystal. 
The thermogram of GCM aspartame and GCM-APM can be seen in fig. 6.  
 
 
Fig. 6: The thermogram of GCM, APM, GCM-APM cocrystal 
 
In the thermogram, there was an endothermic peak of pure GCM on 
171.96 °C indicating the melting point of GCM. The endothermic 
peak of APM was on 240.80 °C, indicating that the APM melting point 
was lower than pure GCM. GCM-APM melting point also was lower 
than pure GCM; it was 196.65 °C. The changes in the melting point of 
GCM indicate the crystal changes in GCM and the possible formation 
of GCM cocrystal [24].  
The XRD of GCM, APM and GCM-APM can be seen in fig. 7. 
 
 
Fig. 7: The XRD of GCM (red), APM (blue) and GCM-APM (black) 
The intensity diffraction pattern for the 1:2 GCM-APM cocrystal 
shows different diffraction pattern when compared with the 
intensities of GCM or APM. X-ray diffraction (XRD) was used to show 
differences in the shape of the cocrystal compared with pure active 
GCM. X-ray diffraction (XRD) is used to analyze polymorphisms and 
to determine changes in the properties of a cocrystal or to determine 
whether a new phase of the cocrystallization process has occurred. 
When a new phase of crystals forms or different pattern was found, 
the diffractogram indicates the formation of a crystal [25]. 
In addition, different peaks formed for pure GCM and the cocrystal 
[26, 27]. It can be concluded that new peaks form and the formation 
of these new peaks or different diffraction pattern can predict the 
formation of a cocrystal [9, 10]. 
CONCLUSION 
Preparation of the GCM-APM cocrystal (1:2) was conducted using the 
solvent evaporation method. The solubility and dissolution test of GCM-
APM cocrystal (1:2) increased significantly compared to pure GCM and 
its physical mixture. The FT-IR, DSC, and PXRD confirmations of the 
cocrystal GCM-APM (1:2) indicated the formation of new solid crystalline 
phases that differ from pure GCM and its physical mixture. 
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